Values, challenges, and responses associated with high-priced potential cures: perspectives of diverse stakeholders in South Korea.

BACKGROUND: The emergence of high-priced potential cures has sparked significant health policy discussions in South Korea, where the healthcare system is funded through a single-payer National Health Insurance model. We conducted focus group interviews (FGIs) and accompanying surveys with diverse stakeholders to comprehensively understand related issues and find better solutions to the challenges brought by these technologies. METHODS: From October to November 2022, 11 FGIs were conducted with stakeholders from various sectors, including government payers, policy and clinical experts, civic and patient organisations, and the pharmaceutical industry, involving a total of 25 participants. These qualitative discussions were supplemented by online surveys to effectively capture and synthesise stakeholder perspectives. RESULTS: Affordability was identified as a critical concern by 84% of stakeholders, followed by clinical uncertainty (76%) and limited value for money (72%). Stakeholders expressed a preference for both financial-based controls and outcome-based pricing strategies to mitigate these challenges. Despite the support for outcome-based refunds, payers raised concerns about the feasibility of instalment payment models, whether linked to outcomes or not, due to the specific challenges of the Korean reimbursement system and the potential risk of 'cumulative liabilities' from ongoing payments for previously administered treatments. In addition, the FGIs highlighted the need for clear budgetary limits for drugs with high uncertainties, with mixed opinions on the creation of special silo funds (64.0% agreement). Less than half (48%) endorsed the use of external reference pricing, currently applied to such essential drugs in South Korea. A significant majority (84%), predominantly non-pharma stakeholders, advocated for addressing cost-effectiveness uncertainty through re-assessment once long-term clinical data become available. CONCLUSIONS: This study uncovers a broad agreement among stakeholders on the need for more effective value assessment methodologies for high-priced potential cures, stressing the importance of more robust and comprehensive re-assessment supported by long-term data collection, rather than primarily relying on external reference pricing. Each type of stakeholders exhibited a cautious approach to their specific uncertainties, suggesting that new funding strategies should accommodate these uncertainties with predefined guidelines and agreements prior to the initiation of managed entry agreements.

The areas of life dissatisfaction and their relationships to depression at different life stages: findings from a nationally representative survey.

This study examined the areas of life dissatisfaction and their relationships to depression at different life stages in men and women, independently of socio-demographic characteristics in South Korea. Data were taken from the 2016 Korea Welfare Panel Study. Depression was assessed using the 11-items of the Center for Epidemiologic Studies Depression Scale (CES-D) and probable depression was defined as the CES-D-11 score of ≥9. Level of satisfaction was measured in seven different life domains (health, family income, residential environment, family relationship, occupation, social relationship and leisure activities) using a 5-point Likert scale. Dissatisfaction was defined as 'very dissatisfied' and 'dissatisfied'. Respondents were grouped into: young (19-39 years; n = 2,713), middle-aged (40-64; n = 4,864) and older adults (65+; n = 4,669). The mean age of the participants was 56.0 years (SD = 18.6) and 57.1% were female (unweighted). The mean CES-D-11 score was 3.5 (SD = 4.8) and 13.7% (n = 1,675) had probable depression (unweighted). The percentage of domain-specific dissatisfaction was highest in family income (28.7%), followed by health (15.9%), leisure activities (14.9%), occupation (11.6%), residential environment (10.2%), social relationship (3.5%) and family relationship (3.0%) (weighted). These percentages were similar across all age groups, except for health and family income in both sexes. In addition, the association between domain-specific dissatisfaction and probable depression was generally stronger in women than in men across all age groups. Logistic regression results (weighted) showed that dissatisfaction with health and leisure activities were consistently associated with probable depression across almost all age groups in both sexes. In addition, family relationship appeared more important in older women, whereas social relationship appeared more important in older men. Meanwhile, dissatisfaction with family income and occupation did not appear to consistently predict depression above and beyond objective indicators, except for older women. Taken together, these findings would help develop sex- and age-specific policies to tackle depression in South Korea.

Relative importance of the EQ-5D five dimensions among patients with chronic diseases in South Korea - a comparison with the general population preference weights.

BACKGROUND: Who should provide the values of health states in economic evaluations of health technologies has long been the subject of debate. This study examined and compared the relative importance of the EQ-5D five dimensions, using both patient-reported values and general population tariffs, among patients with chronic diseases in South Korea and also assessed the pattern of the discrepancy between patient and general population values by type of chronic diseases. METHODS: Data were taken from the 2013 Korea Health Panel survey. This analysis focused on adult patients with chronic diseases (n = 3216). Patient-reported EQ-5D profiles and visual analogue scale (VAS) values were used to assess the relative importance of the EQ-5D five dimensions among these patients, using a linear regression model. The relative importance of the EQ-5D dimensions was then compared to the EQ-5D tariffs elicited from the general population. The relative magnitude of the discrepancies between patient and general population values was also assessed by type of chronic diseases. RESULTS: Anxiety/depression and pain/discomfort appeared to have the largest impact on the self-rated patient VAS, which fairly contrasted with the general population model. In addition, a further regression analysis showed that the discrepancy between patient and general population values varied with the type of chronic diseases. The greatest discrepancy between the two was found in patients with diseases of the blood and blood-forming organs, neoplasms and diseases of the digestive system. CONCLUSIONS: These analyses revealed differences in the relative weights attached to the EQ-5D dimensions between patient groups and the general population, particularly in those 'non-tangible' dimensions. These differences consequently led to greater discrepancies between patient and general population values in certain patient groups, which can have significant implications for resource allocation decisions in South Korea.

The economic burden of advanced gastric cancer in Taiwan.

BACKGROUND: Gastric cancer is one of the leading causes of cancer-related deaths in both sexes worldwide, especially in Eastern Asia. This study aimed to estimate the economic burden of advanced gastric cancer (AGC) in Taiwan. METHODS: The costs of AGC in 2013 were estimated using resource use data from a chart review study (n = 122 with AGC) and national statistics. Annual per-patient costs, where patients' follow-up periods were adjusted for, were estimated with 82 patients who had complete resource use data. The costs were composed of direct medical costs, direct non-medical costs (healthcare travel and caregiver costs), morbidity costs, and mortality costs. Relevant unit costs were retrieved mainly from literature and national statistics, and applied to the resource use data. A broad definition of morbidity and mortality costs was employed to value the productivity loss in patients with unpaid employment, economically inactive and unemployed as well as the life years after the age of retirement. Their narrow definitions were also used in sensitivity analyses, using age- and/or sex-specific employment rates. Forgone future earnings/productivity loss were discounted at 3%. Annual per-patient costs were projected to estimate the total costs of AGC at the national level with an estimated number of patients with AGC (N = 2611) in Taiwan in 2013. RESULTS: The mean age of the 82 patients was 59.3 (SD: 11.9) years, and 67.1% were male. Per-patient costs were US$26,431 for direct medical costs, US$4669 for direct non-medical costs, US$5758 for morbidity costs, and US$145,990 for mortality costs (per death). These per-patient costs were projected to incur total AGC costs of US$423 million at the national-level. Mortality costs accounted for 77.3% of the total costs, followed by direct medical costs (16.3%), morbidity costs (3.6%), and direct non-medical costs (2.9%). CONCLUSION: AGC was found to exert a significant economic burden in Taiwan, incurring US$423 million in 2013. This represents about 0.08% of the Taiwanese economy. Mortality costs appeared to be the single greatest contributor to the burden, followed by direct medical costs. Early detection and providing effective treatments will help to reduce its burden on patients, caregivers and society as a whole. A poster of this study was presented at the 2016 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco, CA, USA.

Functional Impairment and Painful Physical Symptoms in Patients with Major Depressive Disorder Treated with Antidepressants: Real-World Evidence from the Middle East.

BACKGROUND: The Global Burden of Disease 2010 study reported the relative size of major depressive disorder (MDD) burden to be greater in the Middle East and North Africa than anywhere else. However, little research has been carried out to examine the comparative effectiveness of antidepressants in this region. OBJECTIVE: To assess and compare functioning levels in Middle Eastern patients with MDD treated with either duloxetine or a selective serotonin reuptake inhibitor (SSRI), and to examine the impacts of depression-related pain on functioning by the type of treatment. METHOD: This post-hoc analysis, which focused on Middle Eastern patients, used data from a 6-month prospective observational study that included 1,549 MDD patients without sexual dysfunction. Levels of functional impairment and depression-related pain were assessed using the Sheehan Disability Scale (SDS) and the modified Somatic Symptom Inventory, respectively. A mixed model with repeated measures (MMRM) was employed. RESULTS: The mean age of the patients was 37.3 (SD=8.4) years, and 34.6% were female. Patient functioning was, on average, moderately impaired at baseline, but improved substantially during follow-up in both the duloxetine (n=152) and the SSRI (n=123) cohorts. The MMRM results showed a lower level of functional impairment at 24 weeks in the duloxetine cohort than in the SSRI cohort (p<0.001). Pain severity at baseline was positively associated with functional impairment during follow-up only in the SSRI cohort (p=0.003). CONCLUSION: Duloxetine-treated MDD patients achieved better functioning than SSRI-treated patients. This treatment difference was partly driven by depression-related pain.

OH reactivity in urban and suburban regions in Seoul, South Korea - an East Asian megacity in a rapid transition.

South Korea has recently achieved developed country status with the second largest megacity in the world, the Seoul Metropolitan Area (SMA). This study provides insights into future changes in air quality for rapidly emerging megacities in the East Asian region. We present total OH reactivity observations in the SMA conducted at an urban Seoul site (May-June, 2015) and a suburban forest site (Sep, 2015). The total OH reactivity in an urban site during the daytime was observed at similar levels (∼15 s(-1)) to those previously reported from other East Asian megacity studies. Trace gas observations indicate that OH reactivity is largely accounted for by NOX (∼50%) followed by volatile organic compounds (VOCs) (∼35%). Isoprene accounts for a substantial fraction of OH reactivity among the comprehensive VOC observational dataset (25-47%). In general, observed total OH reactivity can be accounted for by the observed trace gas dataset. However, observed total OH reactivity in the suburban forest area cannot be largely accounted for (∼70%) by the trace gas measurements. The importance of biogenic VOC (BVOCs) emissions and oxidations used to evaluate the impacts of East Asian megacity outflows for the regional air quality and climate contexts are highlighted in this study.

Should Unexplained Painful Physical Symptoms be Considered within the Spectrum of Depressive Symptoms?

OBJECTIVE: To examine whether painful physical symptoms (PPS) can be considered within the spectrum of depressive symptoms. METHODS: Data for this post-hoc analysis were taken from a 6-month observational study mostly conducted in East Asia, Mexico, and the Middle East of 1,549 depressed patients without sexual dysfunction at baseline. Both explanatory and confirmatory factor analyses (EFA and CFA) were performed on the combined items of the 16-item Quick Inventory of Depressive Symptomatology Self-Report and the Somatic Symptom Inventory (seven pain-related items only). An additional second-order CFA was also conducted to examine an association between retained factors and the overall "depressive symptoms" factor. In addition, Spearman's correlation was used to assess levels of correlation between retained factors and depression severity as well as quality of life. RESULTS: Both EFA and CFA suggested and validated a four-factor solution, which included a pain factor. The other three factors identified were a mood/cognitive factor, a sleep disturbance factor, and an appetite/weight disturbance factor. All four factors were significantly associated with the overall factor of depression. They were also highly correlated to depression severity and quality of life (p<0.001 for all). The levels of correlations with the pain factor were generally greater than those with the appetite/weight factor and similar to those with the sleep factor. CONCLUSION: It may be reasonable to consider PPS within a broad spectrum of depressive symptoms. At least, they should be routinely assessed in patients with depression. Further research is warranted to validate these preliminary findings.

Characterizations of organic compounds in diesel exhaust particulates.

To characterize how the speed and load of a medium-duty diesel engine affected the organic compounds in diesel particle matter (PM) below 1 µm, four driving conditions were examined. At all four driving conditions, concentration of identifiable organic compounds in PM ultrafine (34-94 nm) and accumulation (94-1000 nm) modes ranged from 2.9 to 5.7 µg/m(3) and 9.5 to 16.4 µg/m(3), respectively. As a function of driving conditions, the non-oxygen-containing organics exhibited a reversed concentration trend to the oxygen-containing organics. The identified organic compounds were classified into eleven classes: alkanes, alkenes, alkynes, aromatic hydrocarbons, carboxylic acids, esters, ketones, alcohols, ethers, nitrogen-containing compounds, and sulfur-containing compounds. At all driving conditions, alkane class consistently showed the highest concentration (8.3 to 18.0 µg/m(3)) followed by carboxylic acid, esters, ketones and alcohols. Twelve polycyclic aromatic hydrocarbons (PAHs) were identified with a total concentration ranging from 37.9 to 174.8 ng/m(3). In addition, nine nitrogen-containing polycyclic aromatic compounds (NPACs) were identified with a total concentration ranging from 7.0 to 10.3 ng/m(3). The most abundant PAH (phenanthrene) and NPACs (7,8-benzoquinoline and 3-nitrophenanthrene) comprise a similar molecular (3 aromatic-ring) structure under the highest engine speed and engine load.

Patient characteristics associated with treatment initiation among paediatric patients with Attention-Deficit/Hyperactivity Disorder symptoms in a naturalistic setting in Central Europe and East Asia.

BACKGROUND: Cultural views of Attention-Deficit/Hyperactivity Disorder (ADHD), differing healthcare systems and funding mechanisms, and the availability of mental health services can greatly influence the perceptions, diagnosis, and treatment of ADHD. There is, however, lack of information about treatment practice and the treatment decision-making process for ADHD, particularly in non-Western countries. Our study compared characteristics of paediatric patients newly diagnosed with ADHD symptoms who did and who did not initiate treatment, and also examined whether any differences varied by region in Central Europe and East Asia. METHODS: Data were taken from a 1-year prospective, observational study that included 1,068 paediatric patients newly diagnosed with ADHD symptoms. Clinical severity was measured using the Clinical Global Impression-ADHD-Severity (CGI-ADHD-S) scale and the Child Symptom Inventory-4 (CSI-4) checklist. Logistic regression was used to explore patient characteristics associated with treatment initiation (pharmacotherapy and/or psychotherapy) at baseline for each region. RESULTS: A total of 74.3% of patients initiated treatment at baseline (78.3% in Central Europe and 69.9% in East Asia). Of these, 48.8% started with both pharmacotherapy and psychotherapy in Central Europe, and only 17.1% did so in East Asia. The level of clinical severity was highest in the combination treatment group in Central Europe, but was highest in the psychotherapy only group in East Asia. In East Asia, treatment initiation was associated with being older, being male, and having a higher CGI-ADHD-S score. In Central Europe, treatment initiation was associated with parental psychological distress, having a higher CSI-4 score, and not being involved in bullying. CONCLUSIONS: Although factors associated with treatment initiation differed to some extent between Central Europe and East Asia, clinical severity appeared to be one of the most important determinants of treatment initiation in both regions. However, the choice between pharmacotherapy and psychotherapy, either alone or in combination, varied substantially across the regions.

Impact of macro-level socio-economic factors on rising suicide rates in South Korea: panel-data analysis in East Asia.

BACKGROUND: The rapid increase in suicide rates in South Korea, particularly in the aftermath of the Asian economic crisis in the late 1990s, compares with the declining suicide rates observed in most other OECD countries over the same period. AIMS OF THE STUDY: This study aimed to examine an array of macro-level societal factors that might have contributed to the rising suicide trend in South Korea. METHODS: We first investigated whether this trend was unique to South Korea, or ubiquitous across five Asian countries/areas that are geographically and culturally similar (South Korea, Hong Kong, Japan, Singapore, and Taiwan), using WHO mortality data and national statistics (1980-2009). Age-standardised suicide rates (per 100,000 population) were calculated for each gender and age group (15-24, 25-44, 45-64, and 65+) for each country. Both panel data and country-specific time-series analyses were employed to investigate the impact of economic change and social integration/regulation on suicide. RESULTS: Despite similarities in geography and culture, the rising trend of suicide rates was unique to South Korea. This atypical trend was most apparent for people aged 65 and over, which was in sharp contrast to the decreasing suicide trends observed in the other four Asian countries. The results of the panel data analyses generally pointed to a negative relationship between economic growth and suicide rates, particularly for working-aged people. The results of the time-series analyses further suggested that low levels of social integration, as indicated by rising divorce rates, may also have a role in rising suicide rates in South Korea, particularly for older people. Furthermore, the association between suicide rates and economic adversity (unemployment and economic downturn) was most salient among middle-aged men in South Korea. DISCUSSION AND LIMITATIONS: Compared to four other East Asian countries/areas (Hong Kong, Japan, Singapore, and Taiwan), South Korea has uniquely experienced a rising trend of suicide rates over the past three decades, particularly among older people. The findings highlight the differential associations between social changes and suicide rates at various stages over a person's life course. Low levels of social integration and economic adversity may in part explain the atypical suicide trend in South Korea, especially for older people and middle-aged men, respectively. Data constraints, however, limit the scope for explanation in light of the complex and multifactorial causes of suicide. IMPLICATIONS FOR HEALTH AND SOCIAL CARE POLICIES: Different age groups within the population require different policy interventions to curb the unprecedented rise in suicide rates in South Korea. Particularly for older people, there is a great need to strengthen methods of assisting family support as well as formulating models of social care that are financially-sustainable and culturally sensitive. More investment is also needed to strengthen labour market protection and/or expand social safety net for the unemployed. IMPLICATIONS FOR FURTHER RESEARCH: The link between social integration and suicide rates deserves further empirical investigation, so that mediating factors that are amenable to policy actions can be better identified.

Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia.

OBJECTIVE: This study assessed the impact of depot formulations on adherence and treating costs in the naturalistic treatment of previously non-adherent outpatients with schizophrenia. METHODS: Data were taken from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Medication adherence and treating costs during an 18-month follow-up were assessed and compared for non-adherent patients initiated on depot typical (n = 262) or oral typical antipsychotics (n = 169) as monotherapy at the index visit. Multivariate analyses were employed to adjust for differences between the two groups at the index visit. RESULTS: Of the previously non-adherent patients, more than half of patients initiated on depot typicals (55%) remained adherent to medication during follow-up, whereas the equivalent was 39% for patients initiated on oral typicals. Logistic regression also showed higher odds of being adherent among the former group (Odds ratio = 1.84; 95% CI = 1.19-2.85). In addition, total costs incurred by this group during 18 months were only half those incurred by patients initiated on oral typicals (£3645 vs £7817, p < 0.05) CONCLUSIONS: Depot formulations of typical antipsychotics appeared to improve medication adherence and reduce treatment costs, compared with oral formulations, in the treatment of non-adherent patients. LIMITATION: adherence was assessed by the treating psychiatrist using a single-item.

Geographical inequalities in suicide rates and area deprivation in South Korea.

BACKGROUND: Recent years have witnessed growing interest in determinants of suicide in South Korea. While much of the research has paid attention to the role of individual factors in explaining suicide mortality, another potentially important dimension of health inequality is geography. AIMS OF THE STUDY: To describe the geographical distribution of suicide rates in South Korea, and to examine to what extent the distribution is shaped by area deprivation. METHODS: Using 2004-2006 mortality data and 2005 population census data, the study first described the spatial mapping of age-standardised suicide rates and level of area deprivation across 250 districts in South Korea. A spatial lag model was also employed to examine the association between the two, taking into account the spatial dependence and interactions between neighbouring districts, as indicated by Moran's I and Geary' C statistics. In addition to level of area deprivation, population density, welfare spending, and rates of divorce, marriage and fertility at district-level were added to the model. RESULTS: The spatial mapping of suicide rates across 250 districts exhibited a different pattern between males and females. While the highest suicide rates tended to cluster in the north-east region of South Korea for males, no clear pattern was observed for females. On the other hand, the lowest suicide rates for both males and females were found in most districts of the capital city. The results of the spatial lag model revealed a significant association between suicide rates and area deprivation, particularly for male suicide. Compared to the least deprived area, there were about 12-13 more male suicide cases (per 100,000 males) in highly deprived areas. The association with area deprivation was less clear for females. Population density was negatively associated with suicide rates for both males and females. While suicide rates were in general positively associated with divorce rates and negatively associated with fertility rates, the coefficients of both were not significant in the model for females. DISCUSSION AND LIMITATIONS: The study highlighted substantial geographical variation in suicide rates across South Korea. Such variation can be largely explained by level of area deprivation, especially for males. The level of excess suicides (i.e. 12-13 per 100,000 males) in highly deprived areas was similar to the average suicide rates of OECD countries. Due to the paucity of individual-level data however, the study was unable to test whether or not these associations were independent of population composition. IMPLICATIONS FOR HEALTH POLICIES: Prioritising development in relatively more deprived areas would potentially minimise resource barriers. Since such area-based approaches focus on a body with clear responsibility (i.e. local authority) and a greater relevance for local residents, programmes and services can be more effectively tailored to local needs and also more effectively delivered to local residents. IMPLICATIONS FOR FURTHER RESEARCH: Alternative sources of data with individual-level data should be explored to strengthen the basis of the present findings, and also to examine the exact mechanism underlying the associations between suicide rates and area deprivation.

The impact of the COVID-19 pandemic on life expectancy by the level of area deprivation in South Korea.

Objective: Comparative evidence suggests that the impact of COVID-19 on life expectancy has been relatively milder in South Korea. This study aims to examine whether the pandemic has universal or unequal impacts on life expectancy across 250 districts with varying levels of deprivation. Methods: Using mortality data from 2012 to 2021 obtained from the Microdata Integrated Service of Statistics Korea, we calculated life expectancy at birth and age 65 for both sexes, by deprivation quintiles, before and during the pandemic. We summarized life expectancy gaps using the slope of the inequality index (SII) and further decomposed the gaps by the contribution of age and cause of death using Arriaga's method. Results: Both men and women experienced consistent improvements in life expectancy from 2012 to 2019, but the trend was disrupted during 2020 and 2021, primarily driven by older people. While men in more deprived areas were initially hit harder by the pandemic, the life expectancy gap across deprivation quintiles remained relatively constant and persistent across the study period [SII: -2.48 (CI: -2.70 from -2.27) for 2019 and - 2.84 (CI: -3.06 from -2.63) for 2020]. Middle-aged men from the most deprived areas were the most significant contributors to the life expectancy gap, with liver disease, liver cancer, transport accidents, and intentional injuries being the leading causes, both in the pre and during the pandemic. While these contributors remained largely similar before and during the pandemic, the contribution of transport accidents and liver cancer to the male life expectancy gap slightly decreased during the pandemic, while that of ischemic heart disease and pneumonia slightly increased. A similar increase was also observed for the female life expectancy gap. Conclusion: This study found no clear evidence of an increased life expectancy gap during the pandemic in South Korea, unlike in other countries, although access to emergency healthcare services may have been slightly more disturbed in deprived areas. This achievement can provide lessons for other countries. However, the persistent regional gaps in life expectancy observed over the past decade indicate the need for more targeted public health policies to address this issue.

Public preferences in healthcare resource allocation: A discrete choice experiment in South Korea.

OBJECTIVES: This study aimed to explore the public view on priority-setting criteria for healthcare resource allocation. Specifically, it investigates how the value of a quality-adjusted life year (QALY) varies depending on patient characteristics. METHODS: A discrete choice experiment was conducted using an online sample of the general South Korean population. Respondents were presented with two competing treatment scenarios. The attributes of the scenarios were age at disease onset, life expectancy without treatment, life-years gain with treatment, health-related quality of life (HRQoL) without treatment, and HRQoL gains with treatment. Two hundred choice sets were generated and randomly allocated into 20 blocks. A conditional logit model was used to estimate the factors affecting the respondents' choices. RESULTS: A total of 3,482 respondents completed the survey. The larger the QALY gain, the more likely it was that the scenario would be chosen but with a diminishing marginal value. Respondents prioritized 40-year-old patients over 5-year-olds and 5-year-olds over 70-year-olds and prioritized baseline HRQoL of 40% and 60% over 20%. Patients at the end of life were not preferred to those with a longer life expectancy. CONCLUSION: Overall, respondents preferred health-maximizing options without explicit consideration for end-of-life patients or those with poor health. In addition, they revealed a kinked preference for patient age, prioritizing middle-aged patients over children and older people.

Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study.

BACKGROUND: With many atypical antipsychotics now available in the market, it has become a common clinical practice to switch between atypical agents as a means of achieving the best clinical outcomes. This study aimed to examine the impact of switching from olanzapine to risperidone and vice versa on clinical status and tolerability outcomes in outpatients with schizophrenia in a naturalistic setting. METHODS: W-SOHO was a 3-year observational study that involved over 17,000 outpatients with schizophrenia from 37 countries worldwide. The present post hoc study focused on the subgroup of patients who started taking olanzapine at baseline and subsequently made the first switch to risperidone (n=162) and vice versa (n=136). Clinical status was assessed at the visit when the first switch was made (i.e. before switching) and after switching. Logistic regression models examined the impact of medication switch on tolerability outcomes, and linear regression models assessed the association between medication switch and change in the Clinical Global Impression-Schizophrenia (CGI-SCH) overall score or change in weight. In addition, Kaplan-Meier survival curves and Cox-proportional hazards models were used to analyze the time to medication switch as well as time to relapse (symptom worsening as assessed by the CGI-SCH scale or hospitalization). RESULTS: 48% and 39% of patients switching to olanzapine and risperidone, respectively, remained on the medication without further switches (p=0.019). Patients switching to olanzapine were significantly less likely to experience relapse (hazard ratio: 3.43, 95% CI: 1.43, 8.26), extrapyramidal symptoms (odds ratio [OR]: 4.02, 95% CI: 1.49, 10.89) and amenorrhea/galactorrhea (OR: 8.99, 95% CI: 2.30, 35.13). No significant difference in weight change was, however, found between the two groups. While the CGI-SCH overall score improved in both groups after switching, there was a significantly greater change in those who switched to olanzapine (difference of 0.29 points, p=0.013). CONCLUSION: Our study showed that patients who switched from risperidone to olanzapine were likely to experience a more favorable treatment course than those who switched from olanzapine to risperidone. Given the nature of observational study design and small sample size, additional studies are warranted.

Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study.

This post hoc study used data from the naturalistic Schizophrenia Outpatient Health Outcomes study, assessing the factors associated with starting antipsychotic monotherapy and the annual rate and duration of antipsychotic monotherapy among patients initiating atypical antipsychotics (N = 6866). Descriptive and regression analyses were used. Factors associated with starting antipsychotic monotherapy at baseline were antipsychotic treatment for the first time, shorter duration of illness, less severe illness, and better social functioning. Baseline monotherapy was maintained throughout 12 months by 63.2% of patients and was significantly greater for olanzapine (66.8%) than for risperidone (62.8%), quetiapine (43.4%), or amisulpride (52.6%) (all p ≤ 0.01). The predicted mean number of days on baseline monotherapy was significantly longer for olanzapine than for risperidone, quetiapine, or amisulpride (all p < 0.01). Initiation of antipsychotic monotherapy at baseline is associated with select baseline patient characteristics. Olanzapine was found to have the highest monotherapy rate and the longest duration of maintained monotherapy, followed by risperidone, amisulpride, and quetiapine.

Systematic Review and Quality Assessment of Health Economic Evaluation Studies (2007-2019) Conducted in South Korea.

BACKGROUND: South Korea formally adopted economic evaluation in December 2006 to aid drug reimbursement decision-making. While this policy change is applied only to pharmaceuticals, it has also sparked interest in economic evaluations for non-pharmaceutical interventions and programmes. OBJECTIVE: This study aimed to provide a snapshot of the current practice for published health economic evaluation studies and critically assess the quality of these studies. METHODS: An electronic search was performed on multiple databases (EMBASE, PubMed, NHS Economic Evaluation Database, Scopus, Korean Medical database, Korean studies Information Service System, and Research Information Sharing Service) to identify health economic evaluation studies published between January 2007 and December 2019. The inclusion criteria were peer-reviewed, original health economic evaluations (cost-utility, cost-effectiveness, cost-minimisation, and cost-benefit analyses) published in English or Korean. Two reviewers selected studies for inclusion and extracted data from the included studies. Key characteristics of these studies were descriptively summarised, and study quality was assessed using the Quality of Health Economic Studies (QHES) instrument on a 100-point scale. RESULTS: A total of 162 studies were included in this review (63 for drugs, 51 for non-pharmaceutical treatments/health technologies, and 48 for health programmes). These numbers confirm a significant increase in the number of publications since the policy introduction. However, the quality of these studies remained relatively low, with a mean QHES score of 57.9 (± 16.0). Study quality also varied substantially, with the QHES scores ranging from 15 to 87. The scores were notably lower in studies with non-pharmaceutical interventions and programmes, cost-effectiveness analyses or cost-benefit analyses, retrospective study-based or simple modelling-based analyses, and those locally published. In addition, a considerable proportion of these studies did not state or specify essential components of economic evaluation, such as perspectives (30.2%), time horizons (29.6%), discount rates (34.6%), and sensitivity analyses (24.7%). While the use of local data either fully or partially was relatively higher for unit costs (94.4%) and resource utilisation (90.1%), it was lower for utility weights (47.1%), treatment effects (63.0%), and baseline risks (70.4%). Transferability or generalisability issues were infrequently discussed when relying on foreign sources. In addition, the included studies were often not well structured, making it difficult to assess their quality. CONCLUSION: These findings suggest that there is still much room for improving the quality of health economic evaluation studies conducted in South Korea. Policymakers should critically evaluate available cost-effectiveness evidence, especially for non-pharmaceutical interventions and programmes, when using it for decision-making in South Korea.

Korean Guidelines for Pharmacoeconomic Evaluations: Updates in the Third Version.

The first version of the pharmacoeconomic (PE) guidelines was published in South Korea in 2006. Despite its first revision in 2011, there were still ambiguities in its interpretation. Moreover, methodologies for estimating effectiveness and costs have also evolved since then. Under these circumstances, the Health Insurance Review and Assessment Service published the third version in January 2021. This article reviews the revision process and major changes made in the new edition of the PE guidelines. The revision was processed through reviews of the previous 50 PE submissions, international guidelines, academic literature, and surveys and advisory meetings to obtain stakeholders' opinions. The analysis perspective has changed from a limited societal perspective to a healthcare system perspective. In addition to the drug with the highest market share, drugs used in clinical trials can be selected as comparators under certain conditions. The discount rate decreased from 5% to 4.5%. Furthermore, the revised guidelines provide more detailed and specific instructions for items including non-inferiority margin, extrapolation, utility elicitation, and uncertainty. Treatment switch and co-dependent technology guidelines are newly included; the budget impact analysis guideline is deleted. Through this revision, transparency and consistency of decision-making is expected to improve.

Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study.

The aim of the present study was to investigate clinical and economic consequences of medication non-adherence during 21-month follow-up in the treatment of bipolar disorder following a manic or mixed episode. Data were taken from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM), which was a prospective, observational study on patient outcomes with a manic/mixed episode in Europe. Physician-rated adherence was dichotomized as adherence/non-adherence at each assessment. Cox proportional hazards models were employed to investigate the impact of non-adherence on remission, recovery, relapse, recurrence, hospitalization and suicide attempts. Costs of medication and resource use in adherent and non-adherent patients during follow-up were estimated with multivariate analyses. Of the 1341 patients analysed, 23.6% were rated non-adherent over 21 months. Non-adherence was significantly associated with decreased likelihood of achieving remission and recovery as well as increased risk of relapse and recurrence as well as hospitalization and suicide attempts. In addition, costs incurred by non-adherent patients during this period were significantly higher than those of adherent patients (£10231 vs £7379, p<0.05). This disparity mainly resulted from differences in inpatient costs (£4796 vs £2150, p<0.05). In conclusion, non-adherence in bipolar patients was associated with poorer long term clinical outcomes that have economic implications for health-care providers.

Comparison of analytical methods and residue patterns of pymetrozine in Aster scaber.

Residues of the polar pesticide pymetrozine were compared using two methods: hydromatrix and liquid-liquid extraction (LLE). The biological half-life and the final residue level were investigated using Aster scaber over a 10-days cultivation period. The respective biological half-lives of the pesticide were 4.2 and 3.5 days at the recommended and double dose. The final residue levels were 1.28 and 1.98 mg kg(-1), respectively, at the same application rate of pymetrozine according to the GAP standard of the United Kingdom. Average recovery was higher with LLE than with the hydromatrix method. Dissipation curves of pymetrozine were influenced by the application amount and growth rate of A. scaber. The final residue level of pymetrozine could be predicted to be lower than the UK maximum residue limit for lettuce applying the GAP standard.